Press release
Lawsuit filed for Investors who lost money with shares of Kyverna Therapeutics, Inc. (NASDAQ: KYTX)
A lawsuit was filed on behalf of investors in Kyverna Therapeutics, Inc. (NASDAQ: KYTX) shares.
Investors who purchased shares of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) have certain options and for certain investors are short and strict deadlines running. Deadline: February 7, 2025. NASDAQ: KYTX investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Emeryville, CA based Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. The Company's lead product candidate is KYV-101.
In early February 2024, Kyverna Therapeutics, Inc conducted its initial public offering (IPO). Kyverna Therapeutics, Inc sold over 16 million shares at $22 per share. Since then shares of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) declined to as low as $3.94 per share on November 19, 2024.
The plaintiff claims that the registration statement and prospectus used to effectuate the Company's IPO misstated and/or omitted facts concerning the results of the Company's ongoing evaluation of KYV-101 in clinical trials, that the Company touted patient "improvement" in certain indicators while failing to disclose adverse data regarding one of Kyverna's trials, which adverse data was known to the Company at the time of the IPO, and that as a result, investors purchased Kyverna shares at artificially inflated prices.
Those who purchased shares of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Lawsuit filed for Investors who lost money with shares of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) here
News-ID: 3847903 • Views: …
More Releases from Shareholders Foundation, Inc.
Lawsuit Alert: Investors who lost money with shares of Molina Healthcare, Inc. ( …
An investor, who purchased shares of Molina Healthcare, Inc. (NYSE: MOH), filed a lawsuit over alleged violations of Federal Securities Laws by Molina Healthcare, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Molina Healthcare, Inc. (NYSE: MOH) have certain options and for certain investors are short and strict deadlines running. Deadline: December 02, 2025. NYSE: MOH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
CTO Realty Growth, Inc. (NYSE: CTO) Long Term Investor Alert: Investigation of p …
An investigation on behalf of current long-term investors in shares of CTO Realty Growth, Inc. (NYSE: CTO) concerning potential breaches of fiduciary duties by certain directors and officers of CTO Realty Growth, Inc. was announced.
Investors who are current long term investors in CTO Realty Growth, Inc. (NYSE: CTO) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a…
Lawsuit filed for Investors who lost money with shares of Marex Group plc (NASDA …
An investor, who purchased shares of Marex Group plc (NASDAQ: MRX), filed a lawsuit in the U.S. District Court for the Southern District of New York over alleged violations of Federal Securities Laws by Marex Group plc in connection with certain allegedly false and misleading statements.
Investors who purchased a significant amount of shares of Marex Group plc (NASDAQ: MRX) between May 16, 2024 and August 5, 2025, have certain options…
LifeMD, Inc. (NASDAQ: LFMD) Investor Alert: Deadline in Lawsuit on October 27, 2 …
A deadline is coming up on October 27, 2025 in the lawsuit filed for certain investors of LifeMD, Inc. (NASDAQ: LFMD) over alleged securities laws violations by LifeMD, Inc.
Investors who purchased shares of LifeMD, Inc. (NASDAQ: LFMD) have certain options and there are strict and short deadlines running. Deadline: October 27, 2025. LifeMD, Inc. (NASDAQ: LFMD) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -…
More Releases for Kyverna
Myasthenia Gravis Pipeline Outlook Report 2025: Latest Clinical Progress and Mar …
DelveInsight's "Myasthenia Gravis Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Myasthenia Gravis pipeline landscape. It covers the Myasthenia Gravis Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Myasthenia Gravis Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious about the latest updates in…
Myasthenia Gravis Pipeline Drugs Report 2025: Emerging Therapies, Clinical Trial …
DelveInsight's, "Myasthenia Gravis Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Myasthenia Gravis pipeline landscape. It covers the Myasthenia Gravis Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Myasthenia Gravis Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious about the latest updates in…
Lupus Nephritis Clinical Trials, Companies, Therapies, Treatment, Pipeline | Hof …
DelveInsight's, "Lupus Nephritis - Pipeline Insight, 2025" report provides comprehensive insights about 35+ companies and 40+ pipeline drugs in Lupus Nephritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
DelveInsight reports that the Lupus Nephritis pipeline involves over 35…
Investigation announced for Long-Term Investors in shares of Kyverna Therapeutic …
An investigation was announced for long-term investors in shares of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) concerning potential breaches of fiduciary duties by certain directors and officers of Kyverna Therapeutics, Inc.
Investors who are current long term investors in Kyverna Therapeutics, Inc. (NASDAQ: KYTX) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term…
Vasculitis Pipeline: Pioneering Progress with 25+ Leading Companies Developing G …
The Vasculitis market is rapidly advancing and is fueled by groundbreaking research and innovative therapies from companies such as Mitsubishi Tanabe Pharma Corporation, Yake Biotechnology, and Kyverna Therapeutics. These industry pioneers are transforming treatment strategies and redefining the future of Vasculitis, bringing new hope to patients worldwide.
DelveInsight's "Vasculitis Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the Vasculitis market. The report covers disease insights, treatment…
Lupus Nephritis Clinical and Non-Clinical Studies, Key Companies, Therapeutic As …
Lupus Nephritis Pipeline constitutes 35+ key companies continuously working towards developing 40+ Lupus Nephritis treatment therapies, analyzes DelveInsight.
Lupus Nephritis Overview:
Lupus Nephritis (LN) is a severe complication of systemic lupus erythematosus (SLE), an autoimmune disease that disrupts immune tolerance and leads to systemic autoimmunity, damaging multiple organs.
SLE affects approximately 7.4-159.4 people per 100,000, with a prevalence of 1.4% to 21.9%. LN, a type of glomerulonephritis, causes inflammation and scarring…
